Sunshine Lake Pharma Co., Ltd. (06887.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 12.03B

MomentumView details →

1D Return

−2.55%

YTD Return

−17.81%

RSI (14)

49.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 12.03B

RSI (14)

49.6

MomentumView details →

1D Return

−2.55%

YTD Return

−17.81%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Latest newsMore news →

Sunshine Lake Pharma's first domestic insulin glargine received FDA approval and achieved commercial shipment in the United States, securing overseas orders exceeding 18 million units.4d ago

Sunshine Lake Pharma issued a profit warning, expecting a net loss of about 590 million RMB for the first half of 2026, an increase of about 540 million RMB compared to the same period last year.11d ago

Similar companies

国邦医药605507.SH 浙江医药600216.SH Elanco Animal Health IncorporatedELAN Consun Pharmaceutical Group Limited01681.HK Ab&B Bio Tech Co Ltd.02627.HK 健友股份603707.SH Find similar companies →

Latest newsMore news →

Sunshine Lake Pharma's first domestic insulin glargine received FDA approval and achieved commercial shipment in the United States, securing overseas orders exceeding 18 million units.4d ago Sunshine Lake Pharma issued a profit warning, expecting a net loss of about 590 million RMB for the first half of 2026, an increase of about 540 million RMB compared to the same period last year.11d ago Sunshine Lake Pharma's self-developed insulin glargine injection received FDA approval for marketing in the United States.47d ago